<DOC>
	<DOCNO>NCT02618902</DOCNO>
	<brief_summary>A first-in-human clinical trial treat patient multiple sclerosis vaccination tolerogenic dendritic cell ( tolDC ) , generate use Good Manufacturing Practice ( GMP ) conduct . In , feasibility safety administer myelin-derived peptide-pulsed tolDC patient MS assess .</brief_summary>
	<brief_title>A `` Negative '' Dendritic Cell-based Vaccine Treatment Multiple Sclerosis : First-in-human Clinical Trial</brief_title>
	<detailed_description>A phase I dose-escalating clinical trial conduct coordinated comprehensive manner determine safety tolerability , enable selection suitable dose regimen phase II trial . The primary objective phase I study determine whether tolDC-based therapy safe well tolerated establish dose-response , clinical relapse rate , neurological disability ( assess use various scale ) MRI endpoint , measure 12 month . Patients serve control pre- post-vaccination . Completion screen assessment confirmation eligibility criterion take long 6 week . First-line treatment stop 6 week baseline late .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>MS accord 2010 revise McDonald criterion ( 76 ) ; Expanded disability status scale ( EDSS ) 06.5 inclusive ; Disease duration maximum 15 year first sign symptom least 6 month prior enrolment study ; Active MS ( relapse progressive ) : 1 relapse past year and/or least 1 enhance lesion brain MRI past year new enlarge T2 lesion ( ) comparison reference scan maximum 1 year Neurologically stable evidence relapse least 30 day prior start screen throughout screen phase ; Positive T cell reactivity response mix 7 myelinderived peptide ; Able sign inform consent ; Ability comply protocol assessment ; Appropriate venous access . Use adequate contraceptive measure Previous use immunosuppressive cytostatic treatment , include mitoxantrone , alemtuzumab bone marrow transplantation stem cell transplantation time prior enrolment ; Treatment fingolimod natalizumab dimethylfumarate teriflunomide within last 3 month prior study enrolment ; Pregnancy plan pregnancy next 12 month breast feeding ; Drug alcohol abuse ; Inability undergo MRI assessment ; History actual sign immunodeficiency malignancy ; Concurrent clinically relevant cardiac , immunological , pulmonary , neurological , renal major disease ; Hepatitis B , C , HIV , Syphilis tuberculosis Splenectomy ; Dementia severe psychiatric , cognitive behavioral problem comorbidity could interfere compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>patient safety</keyword>
	<keyword>tolerogenic dendritic cell</keyword>
	<keyword>tolDC</keyword>
</DOC>